Xvivo Perfusion AB (publ)
Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidn… Read more
Xvivo Perfusion AB (publ) (XVIPF) - Total Liabilities
Latest total liabilities as of December 2025: $260.00 Million USD
Based on the latest financial reports, Xvivo Perfusion AB (publ) (XVIPF) has total liabilities worth $260.00 Million USD as of December 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Xvivo Perfusion AB (publ) - Total Liabilities Trend (2012–2025)
This chart illustrates how Xvivo Perfusion AB (publ)'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Xvivo Perfusion AB (publ) Competitors by Total Liabilities
The table below lists competitors of Xvivo Perfusion AB (publ) ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hubei Century Network Technology Co Ltd
SHE:300494
|
China | CN¥136.87 Million |
|
LT Foods Limited
NSE:LTFOODS
|
India | ₹34.47 Billion |
|
Guangdong No2 Hydropower Engineering Co Ltd
SHE:002060
|
China | CN¥125.45 Billion |
|
Embla Medical hf
CO:EMBLA
|
Denmark | Dkr848.71 Million |
|
Hunan New Wellful Co Ltd
SHG:600975
|
China | CN¥8.74 Billion |
|
Pagerduty Inc
NYSE:PD
|
USA | $688.45 Million |
|
EFORT Intelligent Equipment Co Ltd
SHG:688165
|
China | CN¥1.94 Billion |
|
Focused Photonics Hangzhou Inc
SHE:300203
|
China | CN¥5.70 Billion |
Liability Composition Analysis (2012–2025)
This chart breaks down Xvivo Perfusion AB (publ)'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.77 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Xvivo Perfusion AB (publ)'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Xvivo Perfusion AB (publ) (2012–2025)
The table below shows the annual total liabilities of Xvivo Perfusion AB (publ) from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $260.00 Million | +5.71% |
| 2024-12-31 | $245.97 Million | -1.84% |
| 2023-12-31 | $250.57 Million | -17.29% |
| 2022-12-31 | $302.95 Million | +17.81% |
| 2021-12-31 | $257.15 Million | +81.28% |
| 2020-12-31 | $141.85 Million | +149.00% |
| 2019-12-31 | $56.97 Million | +23.48% |
| 2018-12-31 | $46.13 Million | +34.87% |
| 2017-12-31 | $34.21 Million | +4.03% |
| 2016-12-31 | $32.88 Million | +70.33% |
| 2015-12-31 | $19.31 Million | -24.34% |
| 2014-12-31 | $25.52 Million | -17.50% |
| 2013-12-31 | $30.93 Million | +20.10% |
| 2012-12-31 | $25.75 Million | -- |